• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医护人员对水痘带状疱疹病毒的免疫力:系统评价与荟萃分析(2024年)

Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024).

作者信息

Riccò Matteo, Ferraro Pietro, Zaffina Salvatore, Camisa Vincenzo, Marchesi Federico, Franzoso Francesca Fortin, Ligori Cosimo, Fiacchini Daniel, Magnavita Nicola, Tafuri Silvio

机构信息

Servizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), AUSL-IRCCS di Reggio Emilia, Via Amendola n.2, 42122 Reggio Emilia, Italy.

Occupational Medicine Unit, Direzione Sanità, Italian Railways' Infrastructure Division, RFI SpA, 00161 Rome, Italy.

出版信息

Vaccines (Basel). 2024 Sep 6;12(9):1021. doi: 10.3390/vaccines12091021.

DOI:10.3390/vaccines12091021
PMID:39340051
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11436139/
Abstract

Healthcare workers (HCWs) are occupationally exposed to varicella zoster virus (VZV), and their inappropriate vaccination status could contribute to an outbreak involving both professionals and the patients they care for, with a potential impact on the general population. Therefore, since 2007, the Advisory Committee on Immunization Practices (ACIP) recommends that all HCWs have evidence of immunity against varicella. The present meta-analysis was therefore designed to collect the available evidence on the seronegative status of VZV among HCWs. PubMed, Scopus, and Embase databases were searched without backward limit for articles reporting on the seroprevalence of VZV among HCWs, and all articles meeting the inclusion criteria were included in a random-effect meta-analysis model. From 1744 initial entries, a total of 58 articles were included in the quantitative analysis (publication range: 1988 to 2024), for a pooled sample of 71,720 HCWs. Moreover, the included studies reported on seroprevalence data on measles (N = 36,043 HCWs) and rubella (N = 22,086 HCWs). Eventually, the pooled seronegative status for VZV was estimated to be 5.72% (95% confidence interval [95% CI] 4.59 to 7.10) compared to 6.91% (95% CI 4.79 to 9.87) for measles and 7.21% (5.36 to 9.64) for rubella, with a greater risk among subjects younger than 30 years at the time of the survey (risk ratio [RR] 1.434, 95% CI 1.172 to 1.756). Interestingly, medical history of either VZV infection/vaccination had low diagnostic performances (sensitivity 76.00%; specificity 60.12%; PPV of 96.12% but PNV of 18.64%). In summary, the available data suggest that newly hired HCWs are increasingly affected by low immunization rates for VZV but also for measles and rubella, stressing the importance of systematically testing test newly hired workers for all components of the measles-pertussis-rubella-varicella vaccine.

摘要

医护人员职业暴露于水痘带状疱疹病毒(VZV),其疫苗接种情况不当可能导致涉及专业人员及其护理患者的疫情爆发,对普通人群产生潜在影响。因此,自2007年以来,免疫实践咨询委员会(ACIP)建议所有医护人员有水痘免疫证据。因此,本荟萃分析旨在收集医护人员中VZV血清阴性状态的现有证据。对PubMed、Scopus和Embase数据库进行检索,不限定时间范围,查找报告医护人员中VZV血清流行率的文章,所有符合纳入标准的文章都纳入随机效应荟萃分析模型。从1744条初始记录中,共有58篇文章纳入定量分析(发表时间范围:1988年至2024年),汇总样本为71720名医护人员。此外,纳入研究还报告了麻疹(N = 36043名医护人员)和风疹(N = 22086名医护人员)的血清流行率数据。最终,VZV的汇总血清阴性状态估计为5.72%(95%置信区间[95%CI]4.59至7.10),麻疹为6.91%(95%CI 4.79至9.87),风疹为7.21%(5.36至9.64),调查时年龄小于30岁的受试者风险更高(风险比[RR]1.434,95%CI 1.172至1.756)。有趣的是,VZV感染/疫苗接种病史的诊断性能较低(敏感性76.00%;特异性60.12%;阳性预测值96.12%,但阴性预测值18.64%)。总之,现有数据表明,新雇佣的医护人员中VZV以及麻疹和风疹的低免疫率影响越来越大,强调了系统检测新雇佣人员麻疹-百日咳-风疹-水痘疫苗所有成分的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/867e57f67f93/vaccines-12-01021-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/35f3d59686f3/vaccines-12-01021-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/a079d3229088/vaccines-12-01021-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/0e1ba6037de9/vaccines-12-01021-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/11372c80b6c0/vaccines-12-01021-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/b4b358105ac2/vaccines-12-01021-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/8a1819d22eab/vaccines-12-01021-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/159007767d1c/vaccines-12-01021-g0A7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/9015d50361dc/vaccines-12-01021-g0A8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/cf5b39331c45/vaccines-12-01021-g0A9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/639b81778d28/vaccines-12-01021-g0A10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/2c02158702d3/vaccines-12-01021-g0A11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/36c56ff363ef/vaccines-12-01021-g0A12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/9d436d686901/vaccines-12-01021-g0A13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/acde3dace41e/vaccines-12-01021-g0A14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/4f6d5832c592/vaccines-12-01021-g0A15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/6649bb99e3dc/vaccines-12-01021-g0A16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/442b9bf513c9/vaccines-12-01021-g0A17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/0db9104a67c9/vaccines-12-01021-g0A18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/fa965c2dff99/vaccines-12-01021-g0A19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/fb8ca8029c67/vaccines-12-01021-g0A20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/c76358ce637f/vaccines-12-01021-g0A21.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/d78c9cd8131e/vaccines-12-01021-g0A22.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/1820a102b869/vaccines-12-01021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/4b947f22e037/vaccines-12-01021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/7745916d478e/vaccines-12-01021-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/ac7ba2a2a255/vaccines-12-01021-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/867e57f67f93/vaccines-12-01021-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/35f3d59686f3/vaccines-12-01021-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/a079d3229088/vaccines-12-01021-g0A2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/0e1ba6037de9/vaccines-12-01021-g0A3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/11372c80b6c0/vaccines-12-01021-g0A4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/b4b358105ac2/vaccines-12-01021-g0A5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/8a1819d22eab/vaccines-12-01021-g0A6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/159007767d1c/vaccines-12-01021-g0A7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/9015d50361dc/vaccines-12-01021-g0A8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/cf5b39331c45/vaccines-12-01021-g0A9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/639b81778d28/vaccines-12-01021-g0A10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/2c02158702d3/vaccines-12-01021-g0A11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/36c56ff363ef/vaccines-12-01021-g0A12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/9d436d686901/vaccines-12-01021-g0A13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/acde3dace41e/vaccines-12-01021-g0A14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/4f6d5832c592/vaccines-12-01021-g0A15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/6649bb99e3dc/vaccines-12-01021-g0A16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/442b9bf513c9/vaccines-12-01021-g0A17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/0db9104a67c9/vaccines-12-01021-g0A18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/fa965c2dff99/vaccines-12-01021-g0A19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/fb8ca8029c67/vaccines-12-01021-g0A20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/c76358ce637f/vaccines-12-01021-g0A21.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/d78c9cd8131e/vaccines-12-01021-g0A22.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/1820a102b869/vaccines-12-01021-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/4b947f22e037/vaccines-12-01021-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/7745916d478e/vaccines-12-01021-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/ac7ba2a2a255/vaccines-12-01021-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0880/11436139/867e57f67f93/vaccines-12-01021-g005.jpg

相似文献

1
Immunity to Varicella Zoster Virus in Healthcare Workers: A Systematic Review and Meta-Analysis (2024).医护人员对水痘带状疱疹病毒的免疫力:系统评价与荟萃分析(2024年)
Vaccines (Basel). 2024 Sep 6;12(9):1021. doi: 10.3390/vaccines12091021.
2
Nosocomial transmission of chickenpox and varicella zoster virus seroprevalence rate amongst healthcare workers in a teaching hospital in China.中国某教学医院水痘-带状疱疹病毒血清阳性率及医护人员医院感染情况调查。
BMC Infect Dis. 2019 Jul 5;19(1):582. doi: 10.1186/s12879-019-4222-x.
3
Performance Characteristics of a Multiplex Flow Immunoassay for Detection of IgG-Class Antibodies to Measles, Mumps, Rubella, and Varicella-Zoster Viruses in Presumptively Immune Health Care Workers.用于检测推定免疫医护人员中麻疹、腮腺炎、风疹和水痘 - 带状疱疹病毒IgG类抗体的多重流式免疫测定法的性能特征
J Clin Microbiol. 2020 Mar 25;58(4). doi: 10.1128/JCM.00136-20.
4
Seroprevalence of Varicella-Zoster Virus and Measles among Healthcare Workers in a Tertiary Medical Center in Korea.韩国一家三级医疗中心医护人员中水痘-带状疱疹病毒和麻疹的血清流行率
Vaccines (Basel). 2022 Nov 18;10(11):1956. doi: 10.3390/vaccines10111956.
5
Attitude toward immunization and risk perception of measles, rubella, mumps, varicella, and pertussis in health care workers working in 6 hospitals of Florence, Italy 2011.2011年意大利佛罗伦萨6家医院医护人员对免疫接种的态度以及对麻疹、风疹、腮腺炎、水痘和百日咳的风险认知
Hum Vaccin Immunother. 2014;10(9):2612-22. doi: 10.4161/21645515.2014.970879. Epub 2014 Oct 30.
6
Seroprevalence of antibodies against varicella zoster virus and rubella virus among newly recruited expatriate healthcare workers: a cross-sectional study.新招募的外籍医护人员中水痘带状疱疹病毒和风疹病毒抗体的血清流行率:一项横断面研究。
BMJ Open. 2018 Mar 22;8(3):e019339. doi: 10.1136/bmjopen-2017-019339.
7
Varicella zoster virus infection among healthcare workers in Taiwan: seroprevalence and predictive value of history of varicella infection.台湾地区医护人员水痘带状疱疹病毒感染:水痘感染史的血清阳性率和预测价值。
J Hosp Infect. 2012 Feb;80(2):162-7. doi: 10.1016/j.jhin.2011.11.011. Epub 2011 Dec 19.
8
Outbreak of varicella-zoster virus infection among Thai healthcare workers.泰国医护人员中水痘-带状疱疹病毒感染的爆发。
Infect Control Hosp Epidemiol. 2007 Apr;28(4):430-4. doi: 10.1086/512639. Epub 2007 Feb 26.
9
Seroprevalence of varicella-zoster virus antibody and immunogenicity of live attenuated varicella vaccine in healthcare workers in Taiwan.台湾地区医护人员水痘-带状疱疹病毒抗体血清阳性率和水痘减毒活疫苗的免疫原性。
J Microbiol Immunol Infect. 2023 Apr;56(2):274-281. doi: 10.1016/j.jmii.2022.09.005. Epub 2022 Oct 3.
10
Varicella zoster virus immunity in multinational health care workers of a Saudi Arabian hospital.沙特阿拉伯一家医院多国医护人员的水痘带状疱疹病毒免疫力
Am J Infect Control. 2003 Oct;31(6):375-81. doi: 10.1016/s0196-6553(02)48204-1.

引用本文的文献

1
Varicella-zoster virus seroprevalence among reproductive-age women in Iran: a meta-analysis and implications for targeted immunization.伊朗育龄妇女中水痘-带状疱疹病毒血清流行率:一项荟萃分析及对靶向免疫的启示
BMC Infect Dis. 2025 Aug 18;25(1):1029. doi: 10.1186/s12879-025-11415-2.
2
The global burden of varicella and herpes zoster in adults aged 65 years and older: a comprehensive analysis based on the global burden of disease 2021.65岁及以上成年人水痘和带状疱疹的全球负担:基于2021年全球疾病负担的综合分析
Aging Clin Exp Res. 2025 Aug 4;37(1):240. doi: 10.1007/s40520-025-03142-0.
3
Vaccination Coverage and Associated Factors of Hepatitis B, Measles-Mumps-Rubella, Varicella, and Tetanus-Diphtheria-Acellular Pertussis Among Primary Health Care Workers in Qatar: A Retrospective Study (2020-2024).

本文引用的文献

1
The Incidence of Herpes Zoster Complications: A Systematic Literature Review.带状疱疹并发症的发病率:一项系统文献综述。
Infect Dis Ther. 2024 Jul;13(7):1461-1486. doi: 10.1007/s40121-024-01002-4. Epub 2024 Jun 19.
2
Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression.重组带状疱疹疫苗的免疫原性:系统评价、荟萃分析和元回归分析
Vaccines (Basel). 2024 May 11;12(5):527. doi: 10.3390/vaccines12050527.
3
The Burden of Herpes Zoster on Hospital Admissions: A Retrospective Analysis in the Years of 2015-2021 from the Abruzzo Region, Italy.
卡塔尔初级卫生保健工作者中乙肝、麻疹-腮腺炎-风疹、水痘和破伤风-白喉-无细胞百日咳疫苗接种覆盖率及相关因素:一项回顾性研究(2020 - 2024年)
Cureus. 2025 Jun 28;17(6):e86901. doi: 10.7759/cureus.86901. eCollection 2025 Jun.
4
Seroprevalence of Varicella-Zoster Virus and the Need for Herpes Zoster Vaccination Among Adults in Saudi Arabia.沙特阿拉伯成年人中水痘-带状疱疹病毒血清阳性率及带状疱疹疫苗接种需求
Cureus. 2025 Mar 21;17(3):e80949. doi: 10.7759/cureus.80949. eCollection 2025 Mar.
5
Risk of Nipah Virus Seroprevalence in Healthcare Workers: A Systematic Review with Meta-Analysis.医护人员中尼帕病毒血清阳性率的风险:一项系统评价与荟萃分析
Viruses. 2025 Jan 9;17(1):81. doi: 10.3390/v17010081.
带状疱疹对住院治疗的负担:来自意大利阿布鲁佐地区2015 - 2021年的回顾性分析
Vaccines (Basel). 2024 Apr 26;12(5):462. doi: 10.3390/vaccines12050462.
4
The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020-2070).意大利 50 年来(2020-2070 年)水痘疫苗覆盖率地区差异相关的临床和经济成本。
Sci Rep. 2024 May 24;14(1):11929. doi: 10.1038/s41598-024-60649-8.
5
Global Measles Surveillance: Trends, Challenges, and Implications for Public Health Interventions.全球麻疹监测:趋势、挑战及对公共卫生干预措施的影响
Infect Dis Rep. 2024 Apr 16;16(2):367-379. doi: 10.3390/idr16020028.
6
Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.巴西 2019-2022 年疫苗接种率低和水痘疫情。
Vaccine. 2024 May 31;42(15):3384-3388. doi: 10.1016/j.vaccine.2024.04.021. Epub 2024 Apr 24.
7
Seroprevalence for Measles, Varicella, Mumps and Rubella in the Trainee Obstetric Population: A Survey in Southern Italy.实习产科人群中麻疹、水痘、腮腺炎和风疹的血清流行率:意大利南部的一项调查
Vaccines (Basel). 2024 Mar 20;12(3):335. doi: 10.3390/vaccines12030335.
8
Notes from the Field: Expanded Laboratory Testing for Varicella - Minnesota, 2016-2023.实地记录:明尼苏达州2016 - 2023年水痘实验室检测范围扩大
MMWR Morb Mortal Wkly Rep. 2024 Mar 21;73(11):245-246. doi: 10.15585/mmwr.mm7311a3.
9
Herpes Zoster Recurrence: A Narrative Review of the Literature.带状疱疹复发:文献综述
Dermatol Ther (Heidelb). 2024 Mar;14(3):569-592. doi: 10.1007/s13555-024-01101-7. Epub 2024 Feb 28.
10
Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.带状疱疹重组疫苗的有效性和安全性:真实世界证据的综述。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2263979. doi: 10.1080/21645515.2023.2263979. Epub 2023 Nov 15.